About The Study: In this exploratory analysis, treatment with finerenone, a nonsteroidal mineralocorticoid receptor antagonist, slowed kidney function decline, reduced albuminuria, and lowered the risk of kidney failure or substantial loss of kidney function in patients with glomerular diseases. These findings suggest an important role for finerenone in preserving kidney function in this population.
Corresponding Author: To contact the corresponding author, Brendon L. Neuen, MBBS, MSc, PhD, email bneuen@georgeinstitute.org.au .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2026.9923)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being presented at the 63rd European Renal Association Congress.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.9923?guestAccessKey=45ba1cd9-3280-445f-878c-1e1585df3fee&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=060526
JAMA